Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pipeline

- PMLiVE

AbbVie’s Produodopa rolled out by NHS England for advanced Parkinson’s patients

The roll out follows NICE’s recommendation of the treatment in October 2023

- PMLiVE

Johnson & Johnson’s Tecvayli receives FDA approval for reduced dosing in multiple myeloma patients

More than 35,000 cases of the blood cancer are expected to be diagnosed in the US this year

- PMLiVE

Pfizer’s Velsipity granted EC approval for ulcerative colitis in patients aged from 16 years

The immune-mediated inflammatory bowel disease affects approximately 2.6 million people in Europe

- PMLiVE

FDA approves Iovance’s Amtagvi as first cellular therapy for advanced melanoma

Amtagvi is now the first one-time, individualised T cell therapy to be approved in the US for a solid tumour cancer

- PMLiVE

Astellas and Kelonia enter CAR-T cell therapy collaboration worth over $800m

As part of the deal, Xyphos will combine its iGPS system with Kelonia’s ACCEL technology

- PMLiVE

GSK’s Omjjara recommended by NICE to treat myelofibrosis patients with anaemia

Myelofibrosis is estimated to affect over 1,900 people in England, Wales and Northern Ireland

- PMLiVE

Sanofi’s investigational frexalimab shows promise in relapsing forms of MS

Results from a mid-stage of the candidate were recently published in the NEJM

- PMLiVE

ICR scientists identify new way to study important driver of breast cancer

Researchers used a technique to identify specific molecular details of biotin-labelled proteins

- PMLiVE

Ipsen’s Onivyde regimen granted FDA approval to treat pancreatic cancer

Around 60,000 people are diagnosed with pancreatic adenocarcinoma in the US every year

- PMLiVE

ICR researchers reveal how advanced breast cancers become resistant to hormone therapy

F404 mutations combined with pre-existing mutations caused resistance to fulvestrant

- PMLiVE

BioNTech and Autolus enter CAR-T cell therapy collaboration worth over $250m

Both companies will leverage their autologous CAR-T cell therapy programmes

- PMLiVE

UK government approves digital pathology for cancer screening programmes

The approval follows a study that showed digital pathology was as effective as microscopy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links